A common clinical observation is that patients who develop significant immune-related toxicities, like colitis or pneumonitis, are frequently the same ones who experience the most profound and durable responses to checkpoint inhibitor therapy.

While median survival improvements in advanced HCC are notable, the truly revolutionary impact of immunotherapy is the creation of a long-term survival "tail" on the Kaplan-Meier curve. Clinicians now manage patients for years, a reality that was nonexistent in the pre-IO era.

An analysis of EMERALD and LEAP trial criteria against real-world HCC cases reveals that a majority of complex patients (e.g., multifocal, large tumors) who could most benefit from combination therapies were ineligible, cautioning clinicians against broad application of trial results.

Injecting a genetic medicine into one tumor can trigger an 'abscopal response,' where the immune system learns to recognize the cancer. This educated immune system then travels throughout the body to find and destroy other metastatic tumors, even those in deep organs like the lungs, which are typically the fatal ones.

Immunotherapy is now inducing complete responses in a small subset of advanced HCC patients. This success presents a novel challenge, as there is no data to guide decisions on treatment duration, forcing difficult discussions about stopping therapy in patients who may be cured.

Standard cancer surgery often removes lymph nodes—the factories producing immune cells. Administering immunotherapy *before* this destructive process is critical. It arms the immune system while it is still intact and capable of mounting a powerful, targeted response against the tumor.

Unlike systemic treatments, which rarely cause pancreatic tumors to shrink on scans, TAMP is demonstrating meaningful radiographic responses. This includes resolving major vessel narrowing, suggesting a more potent local effect and hinting at its potential for converting patients to resectability.

Unlike chemotherapy, neoadjuvant immunotherapy appears more effective than adjuvant therapy because it leverages the in-situ tumor and its associated lymph nodes as a 'training ground.' This allows the immune system to generate a robust, specific anti-tumor response before the primary tumor and nodal basin are surgically removed.

An emerging area of research is intralesional immunotherapy, where anti-PD-1 drugs are injected directly into early-stage cutaneous squamous cell carcinomas. This approach may provide effective local control for tumors in anatomically challenging locations while minimizing systemic toxicity.